+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2019

  • ID: 4866556
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 146 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Accendatech Au Pty Ltd
  • Biogen Inc
  • Chord Therapeutics Sarl
  • H. Lundbeck AS
  • Imstem Biotechnology Inc
  • Orion BioScience Inc
  • MORE
Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2019, provides an overview of the Neuromyelitis Optica (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 1, 6, 12, 3 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Neuromyelitis Optica (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuromyelitis Optica (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuromyelitis Optica (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Accendatech Au Pty Ltd
  • Biogen Inc
  • Chord Therapeutics Sarl
  • H. Lundbeck AS
  • Imstem Biotechnology Inc
  • Orion BioScience Inc
  • MORE
Introduction
Report Coverage
Neuromyelitis Optica (Devic’s Syndrome) - Overview
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development
Accendatech Au Pty Ltd
Ahead Therapeutics SL
Alexion Pharmaceuticals Inc
Apsara Therapeutics
Bio-Thera Solutions Ltd
Biogen Inc
Bionure Farma SL
Boston Pharmaceuticals Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
Endece LLC
EnhanX Biopharm Inc
Ferring International Center SA
H. Lundbeck AS
HanAll Biopharma Co Ltd
ImCyse SA
Imstem Biotechnology Inc
LFB SA
Mitsubishi Tanabe Pharma Corp
NovelMed Therapeutics Inc
Orion BioScience Inc
Thelial Technologies SA
Tolerion Inc
Viela Bio Inc
Yantai RC-Pharmaceutical Co Ltd
Neuromyelitis Optica (Devic’s Syndrome) - Drug Profiles
ABX-1431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1511 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAT-4406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-172767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cladribine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-15107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD19 and CD20 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit C3 and C5 for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-3921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olamkicept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORNx-KI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
satralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telitacicept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
The-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-3052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ublituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products
Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2019: FDA and EMA agree to review Roche’s satralizumab applications
Sep 12, 2019: Roche’s drug mitigates relapse risk in late-stage study for NMOSD
Sep 09, 2019: Viela Bio announces data presentations at the 35th Congress of the European Committee for treatment and research in Multiple Sclerosis
Sep 06, 2019: Viela Bio announces publication in The Lancet of pivotal study results of Inebilizumab in patients with Neuromyelitis Optica Spectrum Disorder
Sep 04, 2019: Genentech to present pivotal data for Satralizumab in Neuromyelitis Optica Spectrum Disorder at ECTRIMS
Sep 04, 2019: Roche to present data for satralizumab in neuromyelitis optica spectrum disorder at ECTRIMS
Aug 28, 2019: Alexion announces upcoming data presentations at 35th Congress of the European Committee for treatment and research in Multiple Sclerosis
Aug 27, 2019: European Commission approves SOLIRIS (eculizumab) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
Aug 27, 2019: Viela Bio announces U.S. FDA accepts for review Inebilizumab biologics license application for neuromyelitis Optica spectrum disorder
Jul 26, 2019: Alexion receives positive CHMP Opinion for SOLIRIS (Eculizumab) for the treatment Of NMOSD
Jun 28, 2019: FDA approves Alexion’s Soliris as first treatment for CNS disease NMOSD
May 07, 2019: Viela Bio presents pivotal study results of Inebilizumab in patients with neuromyelitis optica spectrum isorder in a plenary session at the American Academy of Neurology Annual Meeting
May 03, 2019: New England Journal Of Medicine publishes positive phase 3 PREVENT data for SOLIRIS (Eculizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 29, 2019: Genentech to present on Satralizumab at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
Apr 18, 2019: Viela Bio receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for treatment of Neuromyelitis Optica Spectrum Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accendatech Au Pty Ltd, H2 2019
Table 12: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Ahead Therapeutics SL, H2 2019
Table 13: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Table 14: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Apsara Therapeutics, H2 2019
Table 15: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bio-Thera Solutions Ltd, H2 2019
Table 16: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, H2 2019
Table 17: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bionure Farma SL, H2 2019
Table 18: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H2 2019
Table 19: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chord Therapeutics Sarl, H2 2019
Table 20: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Table 21: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Cour Pharmaceuticals Development Co Inc, H2 2019
Table 22: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Endece LLC, H2 2019
Table 23: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by EnhanX Biopharm Inc, H2 2019
Table 24: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Ferring International Center SA, H2 2019
Table 25: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by H. Lundbeck AS, H2 2019
Table 26: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Table 27: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by ImCyse SA, H2 2019
Table 28: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Imstem Biotechnology Inc, H2 2019
Table 29: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by LFB SA, H2 2019
Table 30: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
Table 31: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by NovelMed Therapeutics Inc, H2 2019
Table 32: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Orion BioScience Inc, H2 2019
Table 33: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Thelial Technologies SA, H2 2019
Table 34: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Tolerion Inc, H2 2019
Table 35: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Viela Bio Inc, H2 2019
Table 36: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019
Table 37: Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H2 2019
Table 38: Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Accendatech Au Pty Ltd
  • Ahead Therapeutics SL
  • Alexion Pharmaceuticals Inc
  • Apsara Therapeutics
  • Bio-Thera Solutions Ltd
  • Biogen Inc
  • Bionure Farma SL
  • Boston Pharmaceuticals Inc
  • Chord Therapeutics Sarl
  • Chugai Pharmaceutical Co Ltd
  • Cour Pharmaceuticals Development Co Inc
  • Endece LLC
  • EnhanX Biopharm Inc
  • Ferring International Center SA
  • H. Lundbeck AS
  • HanAll Biopharma Co Ltd
  • ImCyse SA
  • Imstem Biotechnology Inc
  • LFB SA
  • Mitsubishi Tanabe Pharma Corp
  • NovelMed Therapeutics Inc
  • Orion BioScience Inc
  • Thelial Technologies SA
  • Tolerion Inc
  • Viela Bio Inc
  • Yantai RC-Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll